Last updated on August 2018

Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.


Brief description of study

Investigation of efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis

Clinical Study Identifier: NCT02970942

Contact Investigators or Research Sites near you

Start Over

Novo Nordisk

Novo Nordisk Investigational Site
Moscow, Russian Federation
  Connect »